West Pharmaceutical Services INC

West Pharmaceutical Services announced robust second-quarter 2026 financial results, exceeding expectations with significant increases in net sales and adjusted diluted EPS, leading to raised full-year guidance.

West Pharmaceutical Services, Inc. has entered into an Amended and Restated Technology Exchange and Crosslicense Agreement and two Distributorship Agreements with Daikyo Seiko, Ltd., extending their collaboration for another 10 years.

West Pharmaceutical Services, Inc. provides an update on a material cybersecurity attack, confirming operational recovery and no expected material impact on financial guidance.

West Pharmaceutical Services disclosed a material cybersecurity incident on May 7, 2026, involving data exfiltration and system encryption, leading to temporary operational disruptions.

West Pharmaceutical Services, Inc. reported the outcomes of its 2026 Annual Meeting of Shareholders, including director elections, executive compensation approval, auditor ratification, and a shareholder proposal.

West Pharmaceutical Services announced robust first-quarter 2026 financial results, exceeding expectations and leading to an increase in full-year revenue and EPS guidance.

West Pharmaceutical Services reports strong Q2 2026 results with significant revenue and profit growth, driven by its Proprietary Products segment.

West Pharmaceutical Services reports a significant increase in net sales and operating profit for Q1 2026, driven by strong performance in its Proprietary Products segment.

West Pharmaceutical Services reports robust Q3 2025 sales and margin expansion, alongside ongoing restructuring and a securities class action.

West Pharmaceutical Services, Inc. announced robust second-quarter financial results, showcasing significant net sales and operating profit growth, primarily fueled by its Proprietary Products segment and improved gross profit margins.

West Pharmaceutical Services reports a slight increase in net sales for Q1 2025, while initiating a restructuring plan to optimize operating costs.

West Pharmaceutical Services experienced a slight decrease in net sales and a notable decline in gross profit for the third quarter of 2024, impacted by customer inventory management and a shift in product mix.

West Pharmaceutical Services' 2024 10-K filing reveals a slight decrease in net sales and operating profit, alongside strategic investments in manufacturing capacity and share repurchases.

West Pharmaceutical Services, Inc. files its annual 10-K report and updates its non-qualified deferred compensation plan for designated employees, effective January 1, 2024.

Janet Brutschea Haugen, a Director at West Pharmaceutical Services Inc., reported transactions involving restricted stock units and phantom stock units.

Shane Alden Campbell, SVP of Proprietary Segment at West Pharmaceutical Services, reported transactions involving restricted stock units and common stock.

West Pharmaceutical Services Director Paolo Pucci was granted 791 restricted stock units as part of director compensation.

West Pharmaceutical Services Director Douglas A. Michels acquired 791 restricted stock units as part of director compensation.

West Pharmaceutical Services Director Stephen H. Lockhart acquired 791 shares of common stock via a restricted stock unit grant.

Director Myla Lai Goldman acquired 791 restricted stock units of West Pharmaceutical Services, Inc. as part of director compensation.

West Pharmaceutical Services, Inc. announces its 2026 Annual Meeting of Shareholders, detailing proposals for director elections, executive compensation, auditor ratification, and a shareholder proposal on board leadership.

West Pharmaceutical Services, Inc. delivered robust financial performance in 2025 with over $3 billion in net sales and 8% adjusted-diluted EPS growth, while announcing CEO Eric Green's planned retirement in late 2026.

West Pharmaceutical Services announces its annual shareholder meeting to be held virtually on May 6, 2025, with key voting items including the election of directors and executive compensation.

West Pharmaceutical Services reported a slight decline in organic net sales for 2024 but saw a return to growth in Proprietary Products in the fourth quarter and remains optimistic about future growth drivers.

West Pharmaceutical Services will hold its annual shareholder meeting on April 23, 2024, featuring proposals including the election of directors, executive compensation, and amendments to the company's articles of incorporation.

West Pharmaceutical Services is asking shareholders to vote on director elections, executive compensation, and amendments to the company's articles of incorporation at the upcoming annual meeting.

Vanguard Capital Management has reported a beneficial ownership of 7.48% in West Pharmaceutical Services Inc. common stock as of March 31, 2026.

Vanguard Portfolio Management has reported beneficial ownership of 5.69% of West Pharmaceutical Services Inc. common stock as of March 31, 2026.

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in West Pharmaceutical Services Inc. following an internal realignment.

The Vanguard Group reports a 13.49% beneficial ownership in West Pharmaceutical Services Inc. as of September 30, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, reporting an 8.4% beneficial ownership stake in West Pharmaceutical Services Inc. as of March 31, 2025.